Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIM2CERV phase 3 adjuvant ADXS11-001 after chemoradiation in high-risk locally advanced cervical cancer
2015-004844-20Phase 3Terminated
- Sponsor
- Advaxis, Inc.
- Start
- Feb 2017
- Modality
- Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cervical Cancer (CC) comparing ADXS11-001 with Placebo (2 arms). Primary endpoint: Disease-free survival. Started Feb 2017; status: terminated.
02
Drugs
axalimogene filolisbac
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2015-004844-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004844-20.